This communication describes the preparation of antibodies to human interleukin 2 (IL-2), using as immunogens synthetic peptides derived from the predicted amino acid sequence of IL-2. Rabbits and mice were immunized with protein carrier conjugates of eight chemically synthesized IL-2-derived peptides, each consisting of 13-15 amino acids. The immune antisera were screened in a solid-phase ELISA for reactivity to a native human IL-2. Antibodies to four of the eight peptides were found by a variety of biological and immunochemical criteria to react against human IL-2. Furthermore, an affinity-purified antibody to one of the IL-2 peptides (peptide 84) specifically stained the cytoplasm of phytohemagglutinin-stimulated human peripheral blood lymphocytes or T-leukemic cells (Jurkat). Antibodies to synthetic IL-2 peptides should serve as useful probes for studying this lymphokine and for developing quantitative assays for measuring its levels in biological fluids and its association with disease.
Interleukin 2 (IL-2) or T-cell growth factor (TCGF), a T-cellderived glycoprotein shown originally to support the longterm growth of activated T cells (1, 2) , is believed to provide a universal signal for the proliferation of mature T cells (3) through its binding to specific cell-surface receptors (4) . Furthermore, IL-2 was shown to induce antigen-specific cytotoxic T lymphocytes (5-7), natural killer cells (8) , or lymphokine-activated killer cells (9) , all of which are implicated as effector cells in surveillance against malignancy, to reconstitute functional T-cell responses in athymic nude mice (10) and to assist in the immune T-cell-and chemotherapy-induced elimination of established murine syngeneic leukemias (11) . These activities have suggested the potential use of IL-2 as an immunotherapeutic agent.
Additional clinical interest in IL-2 arose in view of the reported associations between abnormalities in IL-2 production and/or response and several diseases. Such defects were identified in mice (12, 13) and humans (14, 15) with systemic lupus erythematosus, in aged individuals (16, 17) , in children with primary immunodeficiencies (18) , in bone marrow transplant recipients undergoing a graft vs. host reaction (19) , and in parasite-infected mice (20) . 
MATERIALS AND METHODS
Preparation and Bioassay of Human IL-2. IL-2 was prepared by stimulating human tonsilar lymphocytes (2 x 106/ml) for 42 hr with 1% (vol/vol) phytohemagglutinin (PHA; GIBCO), phorbol myristate acetate at 50 ng/ml (P-L Biochemicals), and irradiated (5000 rad; 1 rad = 1 x 10-2 gray) human lymphoblastoid cells (0.5 x 106/ml) (Raji). IL-2 was concentrated and purified by methods essentially similar to those described by Robb et al. (4) . Samples were titrated for IL-2 activity as described (27) using the IL-2-dependent line, CTLL-2, as a source of indicator cells.
Synthesis and Carrier Conjugation of Peptides. Peptides were derived from the published sequence of a human IL-2 gene (24) and synthesized by the Merrifield solid-phase method (28, 29) . The positions of the different peptides along the published IL-2 sequence are given in Table 1 . A cysteine residue was added to the amino or carboxyl terminus of some of the peptides to allow coupling to a protein carrier. The composition of all peptides was confirmed by amino acid analysis. Synthetic peptides were coupled to keyhole limpet hemocyanin or tetanus toxoid by two methods. In the first, the carrier was activated with m-maleimidobenzoyl-Nhydroxysuccinimide ester and subsequently coupled to the peptide through its cysteine residue (30) . In the second method, the peptide was coupled to the carrier through free amino groups, using a 0.04% glutaraldehyde solution.
Immunization and Purification of Antibodies. Rabbits were injected intramuscularly with 300-400 ,g of conjugate in complete Freund's adjuvant, incomplete adjuvant, or in alum (5 mg/ml) on days 0, 14 Binding was specific since a given anti-peptide antibody bound to plates coated with the immunizing peptide or IL-2, but not to an irrelevant peptide. Moreover, preimmune serum or hyperimmune antiserum to unrelated peptides did not bind to IL-2 plates to any significant degree (not shown). The same four peptides that elicited IL-2-reactive antibodies in rabbits also induced the formation of anti-IL-2 antibodies in mice (data not shown). Fig. 1 shows that the reactivity of anti-p84 antiserum against solid phase p84 or IL-2 was specifically inhibited by the homologous peptide in solution (50% inhibition at 10-100 ng of peptide per ml) but not by another peptide, p81. This result indicates that the restricted population of anti-peptide antibodies is also the one reacting with the IL-2.
The antisera that showed reactivity against partially puri- fied tonsil-derived IL-2 were purified on peptide-coupled affinity columns. Anti-peptide and anti-IL-2 coeluted from the column after addition of a glycine/HCI buffer, pH 2.5 (not shown). The affinity-purified antibodies were tested in an ELISA against Jurkat-derived IL-2 purified by gel chromatography and isoelectric focusing and considered to be >90% pure (4) , as well as against recombinant human IL-2 (rIL-2), a gift from Biogen. Antibodies against peptides 82 and 84 and, to a lesser extent, those against peptides 12 and 81 reacted to these IL-2 preparations (not shown).
Correlation of IL-2 Biological Activity with ELISA Immunoreactivity. Four liters of IL-2-containing crude tonsil supernatants were fractionated on an AcA-44 column and individual fractions were tested for biological activity in a TCGF bioassay and for immunoreactivity with anti-peptide antibodies in a solid-phase ELISA. Fig. 2 shows results of a representative experiment with an affinity-purified rabbit antip84 antibody. An excellent correlation between biological activity and immunoreactivity was found and the peaks of the two activity profiles were similar. In contrast, AcA-44-derived fractions of a mock IL-2 preparation did not react to any significant extent with the anti-peptide antibody. Moreover, an excellent correlation between biological activity and immunoreactivity profiles was found after two additional purification steps-namely, Affi-gel blue and DEAE-Sephacel chromatographies (not shown). These results strongly suggest that the antigen recognized by the anti-peptide antibodies in the partially purified IL-2 preparations is IL-2 itself.
Immunoblot Analysis. Crude concentrated tonsil-derived supernatants subjected to immunoblot analysis revealed two closely positioned protein bands, in the molecular weight range of 15,000 to 18,000, which reacted with the anti-p84 antibody (Fig. 3) . Preimmune serum or an irrelevant antibody did not react in a similar way (not shown). Furthermore, biologically active TCGF was eluted in a sharp peak from an almost identical position in the gel (Fig. 4) . These results show that (i) anti-p84 reacts with a protein(s) migrating in a position corresponding to the size of human IL-2, and (ii) this protein and the biological activity of IL-2 comigrate on the gel.
Immunofluorescence of PHA-Stimulated Cells. PHA-stimulated (or control) human PBL or leukemic Jurkat cells were fixed, treated with an affinity-purified rabbit anti-p84 anti- Immunoblot analysis of crude tonsil-derived IL-2-containing supernatants using an affinity-purified anti-p84 antibody. Electrophoretically transferred proteins from a supernatant (concentrated 10OX) reacted with affinity-purified rabbit anti-p84 antibody (5 ,ug/ml). Eluates of 2-mm slices of a parallel gel were tested for IL-2 activity at a dilution of 1:100. Numbers above arrows are M, X 10-3.
body, and then treated with a fluorescein isothiocyanateconjugated goat anti-rabbit IgG. Cytoplasmic staining of PHA-stimulated cells was observed (Fig. 4) . Specificity of this reaction was indicated by our findings that (i) the staining was abolished by preincubation of the anti-p84 antibodies with soluble p84 (20 jig/ml), but not with p81 (not shown);
(ii) unstimulated PBL were not stained; and similarly (iii) PHA-stimulated PBL, treated with an anti-p72 (hepatitis B) antibody, were not stained under the same conditions (not shown). Details of this procedure and its application to the enumeration of IL-2-containing cells will be described in a separate communication (unpublished results).
DISCUSSION
The data presented here show that antibodies reactive with native human IL-2 can be readily raised in rabbits and mice immunized with synthetic peptides derived from the predicted amino acid sequence of a human IL-2 molecule. This sequence was deduced from a recently cloned cDNA coding for human IL-2 (24) and confirmed, at least partially, by direct protein sequence analysis (22, 23 activated human peripheral blood lymphocytes or T-leukemic cells. Taken together, these independent findings show that the anti-peptide antibodies described herein recognize native human IL-2 molecules.
Interestingly, the affinity-purified antibodies to peptides 12, 81, 82, or 84 failed so far to neutralize the biological activity of human IL-2 or to immunoprecipitate it from an IL-2-containing supernatant (unpublished observations). This could be due to one of the following: (l) An amino acid sequence required for biological activity could be missing (completely or partially) from the four peptides that elicited anti-IL-2 antibodies. The need for such a critical sequence to elicit antibodies that protect against foot and mouth disease (34) or inhibit the tyrosine-specific kinase activity of the pp6Osrc transforming protein (35) (22) . This is most probably due to the fact that the affinity of interaction between IL-2 and its cellular receptor (4) is greater by several orders of magnitude from the affinity of interaction between IL-2 and its respective antibody (22) . The preparation of antibodies to other IL-2 peptides may clarify this issue.
The establishment of monoclonal hybridomas producing antibodies to human Jurkat-derived IL-2 was recently reported (22, 23) . One of the critical requirements to ensure success was the use of sufficiently large quantities of purified IL-2 for immunization, thus requiring the preparation and processing of relatively large volumes of culture supernatants (22) . The three monoclonal antibodies characterized in one of these studies (22) appeared to react with distinct epitopes on the IL-2 molecules, but these epitopes have not been identified. In a second study (23) (35) . Using this antibody, it was possible to identify a pentadecapeptide that is necessary for the tyrosine-specific kinase activity of the transforming protein pp6Osrc (35 Proc. Natl. Acad. Sci. USA 81 (1984) two dextran-binding myeloma proteins (38) , or between alloantigenic determinants differing in a single amino acid (39) .
The ability of IL-2 to correct some immunodeficient states (10) , to assist in tumor rejection in vivo (11), and to enhance or stimulate the induction of various types of killer lymphocytes in vitro (5-9) aroused great interest in this lymphokine and suggested that IL-2 may provide an immunotherapeutic tool. Moreover, association of IL-2 abnormalities with various diseases (12) (13) (14) (15) (16) (17) (18) (19) (20) emphasized the need for sensitive and reliable quantitative immunoassays for human IL-2 in a clinical setting. The relative ease in preparing anti-IL-2 antibodies by using synthetic IL-2-derived peptides is encouraging and strongly suggests that such antibodies may be useful in various studies on IL-2, including the establishment of more accurate IL-2 assays and the enumeration of IL-2-producing cells in health and disease.
